Why the study?
Does Tipifarnib reduce extracellular vesicles and reverse TAC-induced heart remodeling in preclinical models?
Does Tipifarnib reduce extracellular vesicles and reverse TAC-induced heart remodeling in preclinical models?
Tipifarnib demonstrates potential as a targeted therapy for cardiac fibrosis and remodeling by inhibiting pathological extracellular vesicle generation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted an editorial in Heart failure / Cardiovascular diseases. Tipifarnib was evaluated on TAC-induced heart remodeling and extracellular vesicle reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: